Rintaro Hashizume

This study identifies CPA4 as a YAP-TEAD-driven effector in NF2-deficient meningioma, showing its role in tumor growth and sensitivity to TEAD inhibitors.

The paper identifies and characterizes FCD-11, a first-in-class COMPASS inhibitor that reduces tumor size and extends survival in breast cancer models.

This study evaluates combination therapy of CDK4/6 and MEK inhibitors in DMG models, finding survival benefits in GEM but not PDX models.

This study shows that disrupting ATM enhances radiation therapy efficacy in p53-mutant DMGs but not p53-wildtype DMGs using mouse models.

The paper shows BMP4 reduces H3K4me3 levels in human neural stem cells by downregulating SETD1A and WDR82, leading to decreased proliferation and increased differentiation.